

(19) AUSTRALIAN PATENT OFFICE

(54) Title
Use of taurine or derivatives thereof for the treatment of alopecia

(51)⁶ International Patent Classification(s)

| | | |
|-----------------------------|--------------------|-------------|
| A61K 31/185 | 1/305 | |
| (2006.01) | 20060101ALI2005100 | |
| A23L 1/30 (2006.01) | 8BMEP | A61K |
| A23L 1/305 (2006.01) | 8/46 | |
| A61K 8/46 (2006.01) | 20060101ALI2005100 | |
| A61K 8/63 (2006.01) | 8BMEP | A61K |
| A61K 8/86 (2006.01) | 8/63 | |
| A61K 9/00 (2006.01) | 20060101ALI2005100 | |
| A61K 9/06 (2006.01) | 8BMEP | A61K |
| A61K 9/08 (2006.01) | 8/86 | |
| A61K 9/107 (2006.01) | 20060101ALI2005100 | |
| A61K 9/14 (2006.01) | 8BMEP | A61K |
| A61K 9/20 (2006.01) | 9/00 | |
| A61K 9/28 (2006.01) | 20060101ALI2005100 | |
| A61K 9/48 (2006.01) | 8BMEP | A61K |
| A61K 31/01 (2006.01) | 9/06 | |
| A61K 31/045 | 20060101ALI2006031 | |
| (2006.01) | OBMJP | A61K |
| A61K 31/07 (2006.01) | 9/08 | |
| A61K 31/195 | 20060101ALI2006031 | |
| (2006.01) | OBMJP | A61K |
| A61K 31/201 | 9/107 | |
| A61K 31/20 (2006.01) | 20060101ALI2006031 | |
| A61K 31/201 | OBMJP | A61K |
| (2006.01) | 9/14 | |
| A61K 31/202 | 20060101ALI2006031 | |
| (2006.01) | OBMJP | A61K |
| A61K 31/23 (2006.01) | 9/20 | |
| A61K 31/232 | 20060101ALI2005100 | |
| (2006.01) | 8BMEP | A61K |
| A61K 31/352 | 9/28 | |
| (2006.01) | 20060101ALI2006031 | |
| A61K 31/353 | OBMJP | A61K |
| (2006.01) | 9/48 | |
| A61K 31/355 | 20060101ALI2005100 | |
| (2006.01) | 8BMEP | A61K |
| A61K 31/375 | 31/01 | |
| (2006.01) | 20060101ALI2006031 | |
| A61K 31/437 | OBMJP | A61K |
| (2006.01) | 31/045 | |
| A61K 31/7048 | 20060101ALI2006031 | |
| (2006.01) | OBMJP | A61K |
| A61K 31/765 | 31/07 | |
| (2006.01) | 20060101ALI2006031 | |
| A61K 33/04 (2006.01) | OBMJP | A61K |
| A61K 33/04 (2006.01) | 31/195 | |
| A61K 33/30 (2006.01) | 20060101ALI2005100 | |
| A61K 45/06 (2006.01) | 8BMEP | A61K |
| A61P 17/14 (2006.01) | 31/20 | |
| A61Q 5/00 (2006.01) | 20060101ALI2006031 | |
| A61Q 7/00 (2006.01) | OBMJP | A61K |
| A61K 31/185 | 31/201 | |
| 20060101AFI2005100 | 20060101ALI2006031 | |
| 8BMEP | A23L | |
| 1/30 | OBMJP | A61K |
| 20060101ALI2005100 | 31/202 | |
| 8BMEP | A23L | |
| 31/23 | OBMJP | A61K |

| | |
|--------------------|-------------------|
| 20060101ALI2006031 | 31/765 |
| 0BMJP | A61K |
| 31/232 | 0BMJP |
| 20060101ALI2006031 | A61K |
| 33/04 | 33/04 |
| 0BMJP | A61K |
| 31/352 | 0BMJP |
| 20060101ALI2006031 | A61K |
| 33/30 | 33/30 |
| 0BMJP | A61K |
| 31/353 | 0BMJP |
| 20060101ALI2006031 | A61K |
| 45/06 | 45/06 |
| 0BMJP | A61K |
| 31/355 | 8BMEP |
| 20060101ALI2006031 | A61P |
| 17/14 | 17/14 |
| 0BMJP | A61K |
| 31/375 | 1BMWO |
| 20060101ALI2006031 | A61Q |
| 5/00 | 5/00 |
| 0BMJP | A61K |
| 31/437 | 8BMEP |
| 20060101ALI2006031 | A61Q |
| 7/00 | 7/00 |
| 0BMJP | A61K |
| 31/7048 | 8BMEP |
| 20060101ALI2006031 | PCT/FR2003/001919 |
| 0BMJP | A61K |

(21) Application No: 2003253075 (22) Application Date: 2003.06.23

(87) WIPO No: W004/000293

(30) Priority Data

| (31) Number | (32) Date | (33) Country |
|-------------|------------|--------------|
| 02/07764 | 2002.06.21 | FR |
| 02/07763 | 2002.06.21 | FR |
| 02/07765 | 2002.06.21 | FR |

(43) Publication Date : 2004.01.06

(43) Publication Journal Date : 2004.03.04

(71) Applicant(s)

Nestec S.A., L'Oreal

(72) Inventor(s)

Duranton, Albert, Breton, Lionel

(74) Agent/Attorney

Davies Collison Cave, GPO Box 4387, Melbourne, VIC, 3001

(56) Related Art

WO 1995026646

US 6261589

EP 652012

(12) DEMANDE INTERNATIONALE PUBLIÉE EN VERTU DU TRAITÉ DE COOPÉRATION
EN MATIÈRE DE BREVETS (PCT)

(19) Organisation Mondiale de la Propriété
Intellectuelle
Bureau international



(43) Date de la publication internationale
31 décembre 2003 (31.12.2003)

PCT

(10) Numéro de publication internationale
WO 2004/000293 A3

(51) Classification internationale des brevets⁷ :
A61K 31/185, A23L 1/30, I/302, I/305, I/304, A61K
7/06, A61P 17/14, A61K 31/375, 31/353, 31/355, 31/20,
31/202, 35/78, 33/30, 31/05

(81) États désignés (national) : AE, AG, AI, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, BZ, CA, CI, CN, CO, CR, CU, CZ,
DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SI, TI, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(21) Numéro de la demande internationale :
PCT/FR2003/001919

(84) États désignés (régional) : brevet ARIPO (GH, GM, KE,
LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), brevet
eurasien (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), brevet
européen (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), brevet OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(22) Date de dépôt international : 23 juin 2003 (23.06.2003)

(25) Langue de dépôt : français

Publiée :

- avec rapport de recherche internationale
- avant l'expiration du délai prévu pour la modification des revendications, sera republiée si des modifications sont reçues

(26) Langue de publication : français

(30) Données relatives à la priorité :
02/07763 21 juin 2002 (21.06.2002) FR
02/07764 21 juin 2002 (21.06.2002) FR
02/07765 21 juin 2002 (21.06.2002) FR

(88) Date de publication du rapport de recherche
internationale: 13 mai 2004

(71) Déposants (pour tous les États désignés sauf US) :
L'OREAL [FR/FR]; 14 rue Royale, F-75008 PARIS (FR).
NESTEC S.A. [CH/CH]; Avenus Nestlé, 55, CH-1800
VIEVEY (CH).

En ce qui concerne les codes à deux lettres et autres abréviations, se référer aux "Notes explicatives relatives aux codes et abréviations" figurant au début de chaque numéro ordinaire de la Gazette du PCT.

(72) Inventeurs; et

(75) Inventeurs/Déposants (pour US seulement) : DURANTON, Albert [FR/FR]; 55 Bis rue du Tir, F-78600
MAISONS-LAFITTE (FR). BRETON, Lionel [FR/FR];
14, rue de Satory, F-78000 Versailles (FR).

(74) Mandataire : NONY & ASSOCIES; 3 rue de Penthièvre,
F-75008 Paris (FR).

(54) Title: USE OF TAURINE OR DERIVATIVES THEREOF FOR THE TREATMENT OF ALOPECIA

(54) Titre : UTILISATION DE LA TAURINE OU DE DERIVES POUR LE TRAITEMENT DE L'ALOPECIE

(57) Abstract: The invention relates to the use of taurine and/or hypotaurine and/or the acceptable salts thereof in an oral composition for the preparation of an oral composition that can be used for the treatment and prevention of ageing of the pilosebaceous unit and/or alopecia.

(57) Abrégé : La présente invention concerne l'utilisation de la taurine et/ou de l'hypotaurine et/ou leurs sels acceptables dans une composition orale, pour la préparation d'une composition orale utile dans le traitement et la prévention du vieillissement de l'unité pilo-sébacée et/ou de l'alopecie.

WO 2004/000293 A3

USE OF TAURINE FOR TREATING ALOPECIA

The present invention relates mainly to the use of taurine and/or hypotaurine in oral compositions for preventing and treating functional disorders of the pilosebaceous unit and especially for preventing and treating alopecia. The invention is also directed toward the use of fatty acid(s), polyphenol and/or extracts containing the same, optionally in combination 10 with taurine in food supplements for treating and preventing these same disorders.

Certain physiological impairments appear with age, seasonal variations, stress and atmospheric attacking 15 factors. They include in particular a reduction in hair density during aging, the number and diameter of the hair stems decreasing. In particular, certain individuals develop alopecia.

20 To prevent hair impairments that appear mainly with age, use has been made hitherto of essential amino acids, which are recognized as being vital as nutrients for the synthesis of keratin in the hair bulb. Thus, methionine, cystine and cysteine are known to have a 25 direct impact on the metabolism of the hair follicle. However, these essential amino acids act on protein synthesis, which is not the only mechanism involved in the phenomenon of alopecia.

30 Among the causes of alopecia, it has in fact been determined that impairment of the perifollicular connective tissue was reflected by rigidification of

the connective sheath, which is thought to explain the miniaturization of the hair follicle, a sign of aging of the pilosebaceous unit.

5 Furthermore, these impairments in the hair are often accompanied by impairment in the condition of the scalp, such as the abundant production of sebum. Hypersecretion of sebum or seborrhea and its consequences, for example acne, often appear during puberty, but may 10 continue into adulthood, especially in women, for hormonal reasons.

These disorders may occur in combination, to varying degrees, in the same individual.

15 To combat alopecia, which characterizes the hair follicle, it has been recommended to use medicinal products that inhibit collagen metabolism. It is known practice especially to use minoxidil, and, at the 20 present time, the mechanism of action of minoxidil, which is known to be able to combat the process of miniaturization of the hair follicle, without being anti-androgenic, is still unknown.

25 To combat the hypersecretion of sebum, local treatments have been proposed, including isotretinoin, but this treatment is not without serious side effects.

It has also been recommended to use antiandrogens 30 against alopecia and hypersecretion of sebum, via the systemic route. However, this type of treatment is not without serious side effects, in particular on the

sexual organs.

For its part, document WO 99/22728 describes numerous compounds, including fatty acids, especially for therapeutic uses. However, the medicinal products have drawbacks associated with the risks inherent in their use, insofar as the medicinal products are xenobiotics. In addition, the medicinal products generally have a highly targeted spectrum of action, whereas the causes 10 of impairment of the pilosebaceous unit are manifold.

Moreover, taurine is described as being a cellular activator for regulating hair cells and is proposed in hair-stimulating compositions for topical application, 15 in document WO 02/24189. However, the taurine used as topical cellular activator has limited effect due to the fact that the loss of cellular activity may be caused by several factors of alopecia. If these factors persist, the temporary effects of a topical application 20 of a cellular activator are limited. Furthermore, compositions for topical use have for their part drawbacks associated with local application. The frequency of the applications is generally higher and the application of these compositions to a large area 25 to be treated may require a certain amount of time.

It has thus been found that there is still a need for active agents that can be administered orally, which are effective in the treatment and/or prevention of the 30 signs of aging of the hair and/or functional disorders of the pilosebaceous unit, and especially alopecia, and which are free of side effects. The pilosebaceous unit

comprises a hair follicle and its sebaceous gland.

The Applicant has demonstrated, surprisingly, firstly that taurine is advantageous in regulating the impairment of the connective tissue of the hair follicle, and may thus be used advantageously in the treatment and prevention of aging of the pilosebaceous unit and/or of alopecia. Specifically, it has been possible to observe that taurine reduces the incorporation of proline without impairing that of leucine; this shows the advantage of taurine for specifically reducing the accumulation of collagen, without impairing the overall synthesis of proteins.

Moreover, the Applicant has also found that extracts rich in polyphenols and/or in fatty acids, used orally, especially as a food supplement, have beneficial activity on disorders arising in the pilosebaceous unit. Oral compositions comprising polyphenols and/or fatty acids may especially prevent the cutaneous activation of testosterone (intacrine) and the increase in sebaceous function resulting therefrom, without any general effect on the genital apparatus or the sexual functions.

25 Moreover, the Applicant has noted that favoring an oral administration made it possible to obtain a hair-loss-preventing effect without inducing a stimulatory effect on the growth of the pilous system other than the hair system. It thus found that an oral administration of the active materials under consideration according to the invention was particularly effective for maintain-

ing a good head of hair by acting on the hair density, i.e. the number of hairs per cm^2 of scalp, and by reducing the heterogeneity of the hair diameters.

5 Thus, according to one of its aspects, the present invention relates to the use of taurine and/or hypotaurine and/or salts thereof that are acceptable in an oral composition, for the preparation of an oral composition that is useful for treating and preventing
10 aging of the pilosebaceous unit and/or alopecia and in particular for preventing or reducing impairment of the connective tissue of the hair follicle that is especially induced by rigidification of the connective sheath.

15

Taurine, hypotaurine or acceptable salts thereof may be used according to the invention, in compositions for oral use, which are useful for reducing or preventing impairment of the hair follicle induced by excessive
20 crosslinking and/or synthesis of natural collagens, for regulating the metabolism and structure of collagens in cutaneous and perifollicular tissue, and in particular in the connective sheath of the hair follicle. In particular, taurine and/or hypotaurine and/or
25 acceptable salts thereof may be used for preventing miniaturization of the hair follicle.

According to one variant of the invention, the taurine and/or hypotaurine and/or acceptable salts thereof are
30 used in combination with at least one of the compounds chosen from fatty acids, polyphenols and extracts comprising the same.

According to another of its aspects, the present invention is also directed toward the use of polyphenol(s) chosen from flavonols, anthocyanins, 5 flavanols, proanthocyanidins and flavanones, and stilbenes, and/or of fatty acid(s) chosen from n-6 and n-3 essential polyunsaturated fatty acids, containing between 18 and 22 carbon atoms, and also esters thereof, and mixtures thereof, and/or of an extract 10 comprising the same, for the preparation of an oral composition, especially a food supplement, that is useful for treating or preventing disorders of the pilosebaceous unit, in particular useful for reducing or preventing seborrhea or even for reducing or 15 preventing hair loss.

These oral compositions are especially advantageous for reducing or preventing the excessive metabolism of androgens in the skin and/or for reducing or preventing 20 the impact of testosterone on the pilosebaceous unit.

The present invention also relates to compositions for oral absorption comprising taurine and/or hypotaurine and/or acceptable salts thereof for oral absorption, 25 said compositions comprising as active agent at least 0.05% to 80% by weight of taurine and/or hypotaurine and/or acceptable salts thereof and an excipient, and being free of vitamin C and also comprising, where appropriate, at least one polyphenol and/or one fatty 30 acid and/or an acceptable salt thereof in an oral composition.

More particularly, the polyphenols are chosen from flavones, flavonols, isoflavones, anthocyanins, flavanols, proanthocyanidins and flavanones, and stilbenes, and the fatty acids are chosen from n-6 and n-3 essential polyunsaturated fatty acids, containing between 18 and 22 carbon atoms, and also esters thereof, and mixtures thereof.

Another aspect of the invention relates to a composition for oral absorption comprising at least one polyphenol chosen from flavonols, anthocyanins, flavanols, proanthocyanidins and flavanones and stilbenes and/or a fatty acid chosen from n-6 and n-3 essential polyunsaturated fatty acid(s), containing between 18 and 22 carbon atoms, and also esters thereof, and mixtures thereof, and/or an extract comprising the same, in combination with taurine and/or hypotaurine and/or acceptable salts thereof for oral absorption and, where appropriate, an excipient.

20

The compositions for oral absorption according to the invention may comprise 0.01% to 30% by weight of taurine and/or hypotaurine and/or acceptable salts thereof, in combination with 0.1% to 50% by weight of extracts comprising at least one polyphenol, and especially with 0.1% to 25% by weight, especially 0.1% to 20% by weight or even 0.1% to 15% by weight of catechins.

30 The compositions for oral absorption according to the invention may especially contain taurine and/or hypotaurine and/or acceptable salts thereof, in combination

with polyphenols in a polyphenol/taurine weight ratio at least equal to 0.5, in particular greater than or equal to 0.75 and especially greater than or equal to 1.

5

Another aspect of the invention relates to a composition for oral absorption comprising at least 0.01% to 30% by weight of taurine and/or hypotaurine and/or acceptable salts thereof, in combination with 10 0.01% to 10% by weight of fatty acids.

According to one particular embodiment, the oral compositions of the invention are food supplements.

15 The present invention is moreover directed toward a cosmetic process for treating and preventing aging of the hair and/or alopecia via the oral administration of taurine and/or hypotaurine and/or salts acceptable for oral administration.

20

According to another of its aspects, the invention relates to a cosmetic process for treating and preventing disorders of the pilosebaceous unit via the oral administration of at least one fatty acid, one 25 polyphenol or an extract comprising the same, optionally in combination with taurine and/or hypotaurine and/or acceptable salts thereof.

In one particular embodiment, the taurine, hypotaurine 30 or acceptable salts thereof is (are) administered at a dose of from 0.5 to 4000 mg per day, as taurine equivalent, the fatty acid(s) is (are) administered at

a dose of from 0.5 to 5400 mg/day and/or the polyphenol(s) is (are) administered at a dose of from 0.5 to 2000 mg/day.

5 According to the invention, the expected effects are achieved without the adverse effects of a medicinal product, inexpensively compared with the price of a treatment with a medicinal product. The oral intake of the active agent(s) allows a more constant effect,
10 without it being necessary to repeat the applications.

More particularly, the efficacy limitations are lifted when this oral intake occurs in the case of individuals in whom has been detected a precursor sign of
15 functional disorder of the pilosebaceous unit, especially alopecia, for instance a state of excessive crosslinking of the perifollicular connective tissue, for example via histology or macrophotography of the scalp.

20 The invention will be understood more clearly on reading the detailed description and the examples that follow.

25 TAURINE AND HYPOTAURINE

Taurine and/or hypotaurine, which is a metabolite thereof, may be used as active agent(s) according to the invention. It is also possible to use salts thereof
30 that are acceptable in such oral compositions. Since the compositions according to the invention are intended to be administered to an individual, these

salts are obviously chosen for their total harmlessness. In this respect, alkali metal or alkaline-earth-metal salts, in particular magnesium, manganese, iron II or zinc salts, are most particularly suitable for 5 the invention.

According to the invention, hypotaurine, or taurine, is used in daily doses ranging from 0.5 to 4000 mg per day and preferably 10 to 500 mg per day. The daily dose is 10 more preferably from about 50 to 150 mg per day. The doses indicated in the present description are doses as taurine equivalent.

POLYPHENOLS

15 Any food-grade polyphenol may be used as polyphenol according to the invention. These compounds are generally derived from plants, and their structures are classified according to the nature of the hydrocarbon-20 based skeleton (Laura Bravo Nutrition Review 1998 56 pp. 317-333, Scalbert A. Williamson G, J. Nutr. 2000 130 2073s 2085s).

According to the invention, the term "polyphenols" more 25 particularly means compounds of flavonoid type, i.e. flavones, flavonols, isoflavones, anthocyanins, flavanols, proanthocyanidins and flavanones, and stilbenes.

Flavonols, anthocyanins, flavanols, proanthocyanidins 30 and flavanones, and stilbenes, are more particularly suitable.

The main flavanols are chosen from catechins and gallo-catechins. Procyanidins are flavonol polymers present in the form of low-degree polymer mixtures. They may be associated with catechins in the plant extracts.

5

Polyphenols or polyphenol mixtures chosen from catechin, epicatechin, epigallocatechin 3-O-gallate, epigallocatechin, epicatechin 3-gallate, procyanidins and proanthocyanidins, and mixtures thereof, are 10 preferably used.

It is particularly advantageous to use catechin monomers as a mixture, where appropriate, with procyanidin oligomers (PCO). Thus, the polyphenols used 15 according to the invention cannot consist solely of catechin monomers.

These provisions of polyphenols may be made from isolated compounds and/or from plant extracts, and 20 mixtures thereof.

According to the invention, plant extracts that can provide all of these polyphenols may be used.

25 More particularly, the catechins are very abundant in tea (*Camellia sinensis*) and grape (*Vitis vinifera*) and other fruit (apple, pear or pine cone (*Pinus maritima*)). Beverages (wine, beer, tea) and chocolate (*Theobroma cacao*) are sources that can constitute 30 provisions of catechins according to the invention.

These polyphenols may be used alone or used in the form

of mixtures, and may be ingested in various forms of nutritional supplements (sugarcoated tablets, gels, soluble powders, gel capsules, wafer capsules, enriched foods, etc.).

5

These dietary polyphenols may be used at doses of from 0.5 to 2000 mg/day, especially from 0.5 to 1000 mg/day and preferably from 20 to 300 mg/day.

10 In particular, these polyphenols may be administered orally in "nutritional" doses, i.e. doses equivalent to the doses absorbed by a person on a balanced diet.

By way of example, mention may be made of an extract of 15 grapeseed containing 40% PCO, an extract of red wine containing 30% total polyphenols and/or an extract of green tea containing 30% catechins.

20 The procyanidin oligomers (PCO) may be used at doses of from 0.5 to 1000 mg/day and preferably 20 to 250 mg/day. They may be provided by an extract of 25 grapeseed, which is dosed according to its PCO content. By way of example, for an extract of grapeseed containing 40% PCO, above, a dose of 150 mg/day, i.e. 25 60 mg/day PCO, is used.

Moreover, the catechins may be used at doses of from 0.5 to 1000 mg/day and preferably 20 to 300 mg/day. They may be provided, for example, by an extract of 30 green tea containing 30% catechins, the extracted dose then being about 375 mg/day, i.e. 112.5 mg/day of catechins.

As examples of daily doses of polyphenols, mention may be made of daily doses of an extract of red wine rich in polyphenolic components (600 mg of powdered extract of red wine: 12 mg PCO/person/day, i.e. 18 mg total polyphenols), daily doses of an extract of grapeseed rich in polyphenolic components (300 mg of powdered extract of red wine: 18 mg PCO/person/day, i.e. 27 mg total polyphenols), daily doses of an extract of green tea rich in polyphenolic components (225 mg of powdered extract of green tea: 67.5 mg of catechins/day).

The polyphenols may be chosen from one of the above categories, and mixtures may also be used. The compositions of food supplements may comprise 0.01% to 10% by weight of at least one polyphenol.

In the case where these polyphenols are administered in combination with taurine and/or hypotaurine, they may be administered in a proportion of 0.1% to 50% by weight per 0.01% to 30% by weight of taurine and/or hypotaurine and/or acceptable salts thereof.

The Applicant has especially demonstrated that the oral administration of a dose of 37 mg/kg/day of a red wine concentrate, which is equivalent to a dose of 220 mg/kg/day for a person weighing 60 kg, had an efficacious effect on hair loss without showing any adverse side effects on the prostate. This is especially illustrated in the examples below.

As stated previously, it is advantageous to use the

polyphenols in combination with taurine in a polyphenol/taurine weight ratio at least equal to 0.5, in particular greater than or equal to 0.75 and especially greater than or equal to 1. More particularly, this 5 weight ratio may range from 0.5 to 2, especially from 0.75 to 1.5 or even from 0.9 to 1.3, and may in particular be about 1.2.

Compositions in accordance with the invention comprising from 0.01% to 30% by weight of taurine and/or hypotaurine and/or acceptable salts thereof, and especially of taurine, in combination with 0.1% to 25% by weight of catechins, especially 0.1% to 20% by weight of catechins present in the form of a plant 15 extract or a mixture of plant extracts, are also found to be most particularly advantageous.

In the particular case of catechins, these compounds may be combined with taurine, hypotaurine and/or salts 20 thereof in a catechin/taurine weight ratio at least equal to 0.4, especially greater than 0.7, or even between 0.7 and 1.5.

FATTY ACIDS

25

According to the invention, "fatty acids" refers to polyunsaturated fatty acids, i.e. any fatty acid containing *cis,cis*-methylene interrupted double bonds.

30 The dietary polyunsaturated fatty acids are defined according to the length of the carbon chain and the position of the double bond. The essential fatty acids

are currently organized into two groups ($\omega 3$ and $\omega 6$) characterized by the position of the unsaturation closest to the terminal methyl group.

5 The fatty acids of two families of essential poly-
unsaturated fatty acids of the n-6 and n-3 fatty acid
families, containing between 18 and 22 carbon atoms,
and also esters thereof and mixtures thereof, are most
particularly suitable for the invention. These fatty
10 acids specifically have the advantage of being
permitted according to the food standards.

Preferably, these fatty acids are not associated with
terpenes or terpene derivatives.

15

For the polyunsaturated fatty acids of the n-6 series,
known as "omega-6" fatty acids, mention may be made of
the first, linoleic acid, containing 18 carbon atoms
and two unsaturations: (18:2 $\omega 6$), and γ -linolenic acid
20 (18:3 $\omega 6$) is also a fatty acid that is particularly
advantageous according to the invention.

The sources of γ -linolenic acid will be chosen from
plant oils (evening primrose oil, borage oil, black-
25 currant pip oil and hemp oil), and extracts of
spirulina, *Spirula maxima* and *S. platensis*.

For the polyunsaturated fatty acids of the n-3 series,
known as "omega-3" polyunsaturated fatty acids, the
30 first is alpha-linolenic acid (18:3 $\omega 3$); stearidonic
acid (C18:4n-3) is also a fatty acid that is
particularly advantageous in the invention.

Plant oils from walnut (*Juglans regia*) and from soybean (*Glycina max*), for example, are rich in omega-3 poly-unsaturated fatty acids in the same respect as fish 5 oils.

The $\omega 3$ polyunsaturated fatty acids are found, via the food chain, in zooplankton, crustaceans/molluscs and fish.

10

Fish oils constitute the main industrial source of EPA (eicosapentaenoic acid = 20:5 $\omega 3$) and DHA (docosahexaenoic acid = 22:6 $\omega 3$). However, microalgal biomasses may also constitute a raw material for extraction of $\omega 3$ 15 fatty acids.

The nutritional quality of the microalgae may be improved by means of a judicious choice of strains and by a metabolic orientation associated with the culture 20 conditions.

The advantage of microalgae is all the greater since they synthesize fatty acids such as EPA and DHA.

25 Preferably, linoleic acid, γ -linolenic acid, linolenic acid, stearidonic acid, crocetin and 5,8,11,14-eicosatetraenoic acid and mixtures thereof or extracts comprising them are used. Thus, the fatty acid(s) and/or the extract(s) may be used alone or as mixtures.

30

The recommended daily doses according to the invention are, for the fatty acids, between 0.5 and 3500 mg/day

and especially between 5 and 1500 mg/day.

The recommended daily doses according to the invention are, for the n-3 fatty acids, between 0.5 and 5 2500 mg/day and preferably 5 to 360 mg/day, and, for the n-6 fatty acids, between 0.5 and 2600 mg/day and preferably 5 to 1200 mg/day.

10 The fatty acids may be chosen from one of the above categories, and mixtures thereof may also be used. The oral compositions may comprise 0.01% to 10% by weight of at least one fatty acid.

15 In the case of a combination with taurine and/or hypo- taurine and/or acceptable salts thereof, the compositions according to the invention may comprise from 0.01% to 30% by weight of taurine and/or hypotaurine and/or acceptable salts thereof with 0.01% to 10% by weight of fatty acids.

20

OTHER ACTIVE AGENT(S)

25 The active agents under consideration according to the invention, namely taurine, hypotaurine or salts thereof, fatty acids, polyphenols and mixtures thereof, may be combined with one or more other active agents such as, especially, vitamins and antioxidants, optionally in the form of complexes.

30 For the purposes of the present invention, the term "active agent" means that the compound under consideration, for example taurine, is used to manifest the

biological and chemical activity intrinsic thereto rather than for a function of vehicle or excipient type.

5 Needless to say, the compositions according to the invention may contain several active agents.

As active agents that may be used, mention may be made of zinc and its salts, especially the sulfate and 10 gluconate, vitamins B5, B6, B8, C, E or PP, β -carotene and carotenoids, garlic extracts in the form of allyl sulfide or ajoene for example, selenium, curcumin, curcuminoids, niacin, lithospermic acid and adenosine.

15 In particular, an antioxidant complex comprising vitamins C and E, zinc or salts thereof, selenium and at least one carotenoid, especially a carotenoid chosen from β -carotene, lycopene, zeaxanthin and lutein, may be used.

20

An antioxidant complex comprising, for example, from 100 to 150 mg of vitamin C per 80 to 120 μ g of selenium, 20 to 50 mg of vitamin E, 10 to 40 mg of zinc and 3 to 10 mg of β -carotene is preferred.

25

However, the compositions according to the invention may advantageously contain less than 1% by weight of vitamin C, or may even be free of vitamin C.

30 The active agents according to the invention may also be combined with known hair-loss-preventing active

agents, and especially compounds that further enhance their activity toward regrowth of the hair and/or stopping hair loss, such as, more particularly, the following compounds:

5

- nicotinic acid esters, more particularly including C₃-C₆ alkyl nicotinates and especially methyl or hexyl nicotinate, benzyl nicotinate or tocopheryl nicotinate;
- 10 - steroidal and nonsteroidal antiinflammatory agents that are well known in the state of the art, and in particular hydrocortisone and its salts and derivatives, and niflumic acid;
- retinoids and more particularly t-trans-retinoic
- 15 acid, also known as tretinoin, isotretinoin, retinol or vitamin A and its derivatives, such as the acetate, palmitate or propionate, motretinide, etretinate and zinc trans-retinoate;
- antibacterial agents more particularly chosen from
- 20 macrolides, pyranosides and tetracyclines, and especially erythromycin;
- calcium antagonists such as Cinnarizine and Diltiazem;
- hormones such as estriol or analogs, or thyroxine
- 25 and its salts;
- antiandrogenic agents such as oxendolone, spironolactone or diethylstilbestrol;
- OH-radical scavengers such as dimethyl sulfoxide;
- esterified oligosaccharides such as those
- 30 described in EP-A-0 211 610 and EP-A-0 064 012;
- hexosaccharidic acid derivatives such as those described in EP-A-0 375 388, in particular gluco-

saccharidic acid;

- glycosidase inhibitors such as those described in EP-A-0 334 586, in particular D-glucaro-1,5-lactam;
- 5 - glycosaminoglycanase and proteoglycanase inhibitors such as those mentioned in EP-A-0 277 428, in particular L-galactono-1,4-lactone;
- tyrosine kinase inhibitors such as those described in EP-A-0 403 238, in particular 1-amido-1-cyano-10 (3,4-dihydroxyphenyl)ethylene.

The active agents of the invention may also be combined with, optionally as a mixture with the others, compounds such as Diazoxide corresponding to 3-methyl-7-chloro[2H]-1,2,4-benzothiadiazine 1,1-dioxide; Spiroxazone or 7-(acetylthio)-4',5'-dihydrospiro{androst-4-ene-17,2'-(3'H)furan}-3-one; phospholipids such as lecithin; salicylic acid and its derivatives described more particularly in French patent No. 2 581 542, and more particularly salicylic acid derivatives bearing an alkyl group containing from 2 to 12 carbon atoms in position 5 of the benzene ring, hydroxycarboxylic or keto carboxylic acids and esters thereof, lactones and the corresponding salts thereof; anthralin, eicos-25 5,8,11-triynoic acids, esters and amides thereof, and minoxidil and its derivatives, which are compounds described in EP 353 123, EP 356 271, EP 408 442, EP 522 964, EP 420 707, EP 459 890, EP 519 819, US 4 139 619 and US 459 812.

30

The above compounds are incorporated into the oral compositions and especially the food supplements

provided that their use as food supplement is possible, and their formulation compatible with that of the active agents of the invention. These additional active agents are used according to the invention at doses 5 that are compatible with their use as food supplements. Thus, for certain compounds, it will be preferred to use them topically, as a supplement to the food supplements of the invention.

10 For the ingestion of the active agent(s), numerous embodiments of oral compositions and especially of food supplements are possible. They are formulated via the usual processes for producing sugarcoated tablets, gel capsules, gels, emulsions, tablets, wafer capsules or 15 liquid solutions, especially drinkable ampules, for example. In particular, the active agent(s) according to the invention may be incorporated into any other form of food supplements or of enriched foods, for example dietary bars, or compacted or noncompacted 20 powders. The powders may be dilutable in water, in soda, dairy products or soybean derivatives, or may be incorporated into dietary bars.

The active agents may be formulated with the common 25 excipients and components for such oral compositions or food supplements, such as, especially, fatty and/or aqueous components, humectants, thickeners, preserving agents, texture, taste and/or coating agents, anti-oxidants, preserving agents and dyes that are common in 30 the food sector.

The formulating agents and excipients for oral

compositions, and especially for food supplements, are known in this field and will not be described in detail.

5 The cosmetic process according to the invention is performed by means of an oral intake, for example daily, of an oral composition or food supplement, which may be, for example, in the form of gel capsules, gels, sugarcoated tablets, emulsions, tablets, wafer capsules
10 or drinkable ampules, in adequate amount and number, depending on their form, such that the taurine and/or hypotaurine or acceptable salts thereof are ingested in a proportion of from 0.5 to 4000 mg per day, preferably 10 to 500 mg per day and more preferably about 150 mg
15 per day, as taurine equivalent, and/or such that the polyphenol(s) is (are) ingested at doses of about from 0.5 to 2000 mg/day, and/or such that the fatty acids are ingested at doses of from 0.5 to 5400 mg per day and preferably from 5 to 1600 mg per day.

20

The process according to the invention may consist of a single intake, but is generally applied over a prolonged period of at least 4 weeks, or even 4 to 8 weeks, with, where appropriate, one or more periods
25 of interruption.

By way of example, for γ -linolenic acid, which may be provided by blackcurrant pip oil, doses of about from 10 to 3000 mg/day and preferably from 50 to 1000 mg/day
30 may be envisioned.

In the description and in the examples that follow,

unless otherwise mentioned, the percentages are weight percentages and the ranges of values mentioned in the form "between ... and ..." include the lower and upper limits mentioned. The ingredients are mixed, before 5 being fashioned, in the order and under conditions that are readily implemented by a person skilled in the art.

The examples and figures given below are presented as nonlimiting illustrations of the field of the 10 invention.

Figure 1: This shows the results of the ingestion of fatty acids by hamsters, in a CVO test.

15 Figure 2: This shows the results of the ingestion of polyphenols by hamsters in a CVO test.

Figure 3: This shows the results of hair-loss prevention found in the case of individuals treated 20 according to the invention and of control individuals.

EXAMPLE TO DEMONSTRATE THE ACTIVITY OF FATTY ACIDS AND POLYPHENOLS

25 In order to demonstrate the activity of these compounds, a test of detection of activity on a specific pilosebaceous formation was used: the CVO test.

The hamster CVO (costovertebral organ) is a cutaneous 30 region rich in pilosebaceous units (hair follicles and the sebaceous glands thereof). The size of this formation is increased under the action of testos-

terone. The test (Liao S. & al. Arch Dermatol Res 2001 Apr; 293(4): 200-205) consists in determining the antiandrogenic action of compounds on the CVO, i.e. in determining whether the compounds prevent the action of 5 testosterone.

1/ CVO test with fatty acids

In this test, blackcurrant pip oil at 10% in feed is 10 given to male hamsters for 85 days. It is found that this nutritional supplement prevents the testosterone-induced increase in the size of the CVO.

Thus, in figure 1, the dashed curve represents the 15 change in the size of the CVO (mm^2) in control animals, without supplementation, during the experiment (days on the x-axis): there is a testosterone-induced increase in the size of the CVO. The solid-line curve shows the change in the size of the CVO in the case of animals 20 with supplementation: this increase is reduced to virtually zero.

2/ CVO test with polyphenols

25 Hamsters were fed a nutrient in the form of Robertet red wine concentrate comprising 18% of flavanoid components (0.11 g in 43 g of feed) daily, and it was found that the right CVO/left CVO difference was virtually zero, at 85 days of ingestion (figure 2).

30

Thus, in figure 2, the dashed curve shows the change in the size of the CVO (mm^2) in the case of control

animals, without supplementation, during the experiment (days on the x-axis): there is a testosterone-induced increase in the size of the CVO. The solid-line curve shows the change in the size of the CVO in the case of 5 animals with supplementation: this increase is reduced to virtually zero.

3/ Absence of sexual side effect

10 In the case of the hamsters that received these oral nutritional supplements, a repercussion of the anti-androgenic action was found not only on the CVO, but also on the sexual organs in the case of male animals. In both cases, it was found that these nutritional 15 supplements did not impair the weight of the seminal vesicles or of the prostate.

EXAMPLE TO DEMONSTRATE THE ACTIVITY OF TAURINE

20 A study was performed with the aim of evaluating, via a screening method, the effects of the compounds on the growth of fibroblasts and the synthesis of the major constituents of the extracellular matrix. The technique made it possible to study and evaluate the advantage of 25 taurine on this cell metabolism (T. Shigematsu et al. Biochimica et Biophysica Acta 1200 (1994) 79-83).

A pool of normal human dermal fibroblasts (NHDF pool PF2, used at the eighth passage) was cultured under 30 standard conditions in a medium: DMEM, 2 mM L-glutamine, 50 IU/ml/50g/ml penicillin/streptomycin, 0.5% fetal calf serum.

Taurine was tested at concentrations of 10 mM and 1 mM in a sterile culture medium, against an untreated control blank.

5

The results of the incorporation of thymidine, proline and leucine into the fibroblasts are given in table I below, which shows the effect of taurine on the incorporation of thymidine, proline and leucine in 10 macromolecules neosynthesized by the NHDFs in *in vitro* culture. The figures in bold are those for which there is a significant variation (stat. sign. meaning statistical significance: $p < 0.005$). The results are expressed as a percentage of the control.

15

Table 1

| | Thymidine | | Proline | | Leucine | |
|---------------|-----------|-------------|-----------|-------------|-----------|-------------|
| | % control | Stat. sign. | % control | Stat. sign. | % control | Stat. sign. |
| 1 mM taurine | 89 | $p > 0.05$ | 88 | $p < 0.01$ | 100 | $p > 0.05$ |
| 10 mM taurine | 90 | $p > 0.05$ | 87 | $p < 0.01$ | 105 | $p > 0.05$ |

It is seen that taurine, at the two treated 20 concentrations, did not significantly modify the incorporation of thymidine, which is representative of the cell proliferation, or of leucine, which is representative of the synthesis of noncollagen protein, by the fibroblasts; on the other hand, taurine did 25 significantly inhibit the incorporation of proline by the fibroblasts.

FORMULATION EXAMPLES

Example 1

FORMULATION OF SUGARCOATED TABLET TYPE

5

| | mg/sugarcoated tablet |
|---|--------------------------|
| Taurine | 50 |
| Excipient for the core of the sugarcoated tablet | |
| Microcrystalline cellulose | 70 |
| Encompress™ | 60 |
| Magnesium stearate | 3 |
| Anhydrous colloidal silica | 1 |
| Coating agent | |
| Shellac | 5 |
| Talc | 61 |
| Sucrose | 250 |
| Polyvidone | 6 |
| Titanium dioxide | 0.3 |
| Colorant | 5 |

This type of sugarcoated tablet may be taken 2 to 3 times a day.

10 Example 2

PLANT OR ANIMAL GELATIN GEL CAPSULE

| Active principle | mg/sugarcoated tablet |
|--------------------|-----------------------|
| Taurine | 80 |
| Starch | 128 |
| Magnesium stearate | 2.5 |

This type of gel capsule may be taken two or three times a day.

5 Example 3

SINGLE-DOSE GEL

| Active principle | wt% |
|---------------------------------|--------|
| Taurine | 4 |
| Zinc-enriched yeast (22.75% Zn) | 2 |
| | |
| Excipient | |
| Rhodigel™ | 2:3 |
| Cocoa extract | 20 |
| Potassium sorbate | 0.05 |
| Sodium benzoate | 0.05 |
| Water | qs 100 |

10 200 to 400 ml of this product may be used per day.

Example 4

SINGLE-DOSE GEL

15

| Active principle | wt% |
|------------------|-----|
| Taurine | 4 |

| | |
|----------------------|--------|
| Blackcurrant pip oil | 10 |
| | |
| Excipient | |
| Sugar syrup | 50 |
| Maltodextrin | 17 |
| Xanthan gum | 0.8 |
| Sodium benzoate | 0.2 |
| Water | qs 100 |

200 to 400 ml of this product may be used per day.

Example 5

5

SINGLE-DOSE GEL

| Active principle | wt% |
|----------------------|--------|
| Taurine | 4 |
| Blackcurrant pip oil | 10 |
| Antioxidant complex | * |
| Excipient | |
| Sugar syrup | 50 |
| Maltodextrin | 17 |
| Xanthan gum | 0.8 |
| Sodium benzoate | 0.2 |
| Water | qs 100 |

* The antioxidant complex comprises 120 mg of vitamin C, 100 µg of selenium, 30 mg of vitamin E, 20 mg of zinc and 6 mg of β-carotene per 200 ml of gel.

200 to 400 ml of this product may be used per day.

Example 6**WAFER CAPSULE**

5

| | mg/capsule |
|------------------------|------------|
| Taurine | 50 |
| Zinc gluconate | 160 |
| Wine extract (20% PCO) | 300 |
| Glycerol | 150 |
| Magnesium stearate | 0.02 |
| Water | qs 900 mg |

Example 7**WAFER CAPSULE**

10

| | mg/capsule |
|------------------------|------------|
| Taurine | 50 |
| Zinc gluconate | 160 |
| Wine extract (20% PCO) | 300 |
| Glycerol | 150 |
| Magnesium stearate | 0.02 |
| Vitamin complex | qs * |
| Water | qs 900 mg |

* The vitamin complex comprises 60 mg of vitamin C, 50 µg of selenium, 15 mg of vitamin E, 10 mg of zinc and 3 mg of lycopene.

Example 8

FORMULATION OF SUGARCOATED TABLET TYPE

| | mg/sugarcoated tablet |
|---|--------------------------|
| Taurine | 50 |
| Grapeseed extracts (40% PCO) | 100 |
| Green tea extracts (30% catechins) | 125 |
| Zinc sulfate (22.75%) | 22 |
| | |
| Excipient for the core of the sugarcoated tablet | |
| Microcrystalline cellulose | 70 |
| Encompress™ | 60 |
| Magnesium stearate | 3 |
| Anhydrous colloidal silica | 1 |
| | |
| Coating agent | |
| Shellac | 5 |
| Talc | 61 |
| Sucrose | 250 |
| Polyvidone | 6 |
| Titanium dioxide | 0.3 |
| Colorant | 5 |

5

This type of sugarcoated tablet may be taken 1 to 3 times a day.

Example 9

FORMULATION OF SUGARCOATED TABLET TYPE

| | mg/sugarcoated tablet |
|---|--------------------------|
| Grapeseed extracts (40% PCO) | 100 |
| Green tea extracts (30% catechins) | 125 |
| Zinc sulfate (22.75%) | 22 |
| | |
| Excipient for the core of the sugarcoated tablet | |
| Microcrystalline cellulose | 70 |
| Encompress™ | 60 |
| Magnesium stearate | 3 |
| Anhydrous colloidal silica | 1 |
| | |
| Coating agent | |
| Shellac | 5 |
| Talc | 61 |
| Sucrose | 250 |
| Polyvidone | 6 |
| Titanium dioxide | 0.3 |
| Colorant | 5 |

5

This type of sugarcoated tablet may be taken once or twice a day.

Example 10**FORMULATION OF SUGARCOATED TABLET TYPE**

| | mg/sugarcoated tablet |
|---|----------------------------------|
| Taurine | 50 |
| Grapeseed extracts (40% PCO) | 50 |
| Green tea extracts (30% catechins) | 125 |
| Zinc sulfate (22.75%) | 22 |
| | |
| Excipient for the core of the sugarcoated tablet | |
| Microcrystalline cellulose | 70 |
| Encompress™ | 60 |
| Magnesium stearate | 3 |
| Anhydrous colloidal silica | 1 |
| | |
| Coating agent | |
| Shellac | 5 |
| Talc | 61 |
| Sucrose | 250 |
| Polyvidone | 6 |
| Titanium dioxide | 0.3 |
| Colorant | 5 |

5

This type of sugarcoated tablet may be taken 1 to 3 times a day.

Example 11

PLANT OR ANIMAL GELATIN GEL CAPSULE

| Active principle | mg/gel capsule |
|-----------------------------------|----------------|
| Grapeseed extract (40% PCO) | 50 |
| Green tea extract (30% catechins) | 175 |
| Starch | 128 |
| Magnesium stearate | 2.5 |

5

One to four gel capsules may be taken per day.

Example 12

10 PLANT OR ANIMAL GELATIN GEL CAPSULE

| Active principle | mg/gel capsule |
|-----------------------------------|----------------|
| Taurine | 80 |
| Grapeseed extract (40% PCO) | 50 |
| Green tea extract (30% catechins) | 175 |
| Starch | 128 |
| Magnesium stearate | 2.5 |

One to four gel capsules may be taken per day.

Example 13**SINGLE-DOSE GEL**

| Active principle | wt% |
|-----------------------------------|------------|
| Taurine | 4 |
| Grapeseed extract (40% PCO) | 4 |
| Green tea extract (30% catechins) | 6 |
| Zinc-enriched yeast (22.75% Zn) | 2 |
| | |
| Excipient | |
| Rhodigel™ | 2.3 |
| Cocoa extract | 20 |
| Potassium sorbate | 0.05 |
| Sodium benzoate | 0.05 |
| Water | qs 100 |

5

200 to 400 ml of gel are taken per day.

Example 1410 **SINGLE-DOSE GEL**

| Active principle | wt% |
|-----------------------------------|------------|
| Grapeseed extract (40% PCO) | 4 |
| Green tea extract (30% catechins) | 10 |
| Blackcurrant pip oil | 10 |
| | |
| Excipient | |
| Sugar syrup | 50 |
| Maltodextrin | 17 |

| | |
|-----------------|--------|
| Xanthan gum | 0.8 |
| Sodium benzoate | 0.2 |
| Water | qs 100 |

200 to 400 ml of gel are taken per day.

Example 15

5

WAFER CAPSULE

| | mg/capsule |
|------------------------|------------|
| Taurine | 50 |
| Zinc gluconate | 60 |
| Wine extract (20% PCO) | 300 |
| Glycerol | 150 |
| Magnesium stearate | 0.02 |
| Water | qs 900 mg |

One to four wafer capsules are taken per day.

10

Example 16

POWDERS

15 A 1.8 g wine extract providing up to 540 mg of total polyphenols (including 360 mg of PCO), up to 120 mg of taurine, 0.01 g of Goldblend sweetener, 0.4 g of FRAM0584 flavoring and 4 g of maltodextrin was used in the form of a powder to be diluted in water, in a dairy product or incorporated into a cereal/fruit dietary bar to be consumed each day.

20

Under the same conditions, the following were used:

- A mixture of extracts of *Vitis vinifera* and/or of a biotechnological product thereof (grape juice, wine, etc.) providing the same amount of total polyphenols in combination with a source of taurine-rich natural proteins providing an amount of taurine of 150 mg/day.
- An extract of *Camellia sinensis* or of *Theobroma cacao* providing the same amount of total polyphenols, in combination with a source of taurine-rich natural proteins providing the same amount of taurine.

Example 17

15 A vitamin complex comprising 120 mg of vitamin C, 100 µg of vitamin E, 20 mg of zinc and 6 mg of β -carotene, in 200 ml of gel from example 5 and 60 mg of vitamin C, 50 µg of vitamin E, 10 mg of zinc and 3 mg of β -carotene in a sugarcoated tablet of example 10 is 20 added to the gel formulation of example 13.

Example 18

In the formulations of example 17, the β -carotene is 25 replaced with lycopene.

Example 19

SINGLE-DOSE GEL

| Active principle | wt% |
|-----------------------------------|--------|
| Taurine | 4 |
| Grapeseed extracts (40% PCO) | 4 |
| Green tea extract (30% catechins) | 6 |
| Blackcurrant pip oil | 10 |
| | |
| Excipient | |
| Sugar syrup | 50 |
| Maltodextrin | 17 |
| Xanthan gum | 0.8 |
| Sodium benzoate | 0.2 |
| Water | qs 100 |

A dose of 200 to 400 ml may be taken per day.

Example 20

5

WAFER CAPSULE

| | mg/capsule |
|------------------------|------------|
| Taurine | 50 |
| Zinc gluconate | 60 |
| Wine extract (20% PCO) | 200 |
| Blackcurrant pip oil | 300 |
| Glycerol | 150 |
| Magnesium stearate | 0.02 |
| Natural flavoring | |
| Water | qs 900 mg |

10 One to three of these wafer capsules may be taken per

day.

Example 21

5 FORMULATION OF SUGARCOATED TABLET TYPE

| | mg/sugarcoated tablet |
|---|--------------------------|
| Taurine | 50 |
| Grapeseed extracts (40% PCO) | 50 |
| Green tea extracts (30% catechins) | 125 |
| Zinc sulfate (22.75%) | 22 |
| | |
| Excipient for the core of the sugarcoated tablet | |
| Microcrystalline cellulose | 70 |
| Encompress™ | 60 |
| Magnesium stearate | 3 |
| Anhydrous colloidal silica | 1 |
| | |
| Coating agent | |
| Shellac | 5 |
| Talc | 61 |
| Sucrose | 250 |
| Polyvidone | 6 |
| Titanium dioxide | 0.3 |
| Colorant | 5 |

This type of sugarcoated tablet may be taken 1 to 3 times a day.

Example 22

5 A vitamin complex comprising 120 mg of vitamin C, 100 µg of vitamin E, 20 mg of zinc and 6 mg of β-carotene, per 200 ml of gel, is added to the formulation of example 19.

Example 23

10 A vitamin complex comprising 120 mg of vitamin C, 100 µg of vitamin E, 20 mg of zinc and 6 mg of lycopene, per 200 ml of gel, is added to the formulation of example 19.

15 Example 24

20 A vitamin complex comprising 60 mg of vitamin C, 50 µg of vitamin E, 10 mg of zinc and 3 mg of lycopene, for a sugarcoated tablet, is added to the formulation of example 22.

Example 25**FORMULATION OF TABLET TYPE**

25

| Active principle | Mg/tablet |
|------------------------------------|-----------|
| Taurine | 75 |
| Grapeseed extracts (40% PCO) | 75 |
| Green tea extracts (30% catechins) | 187.5 |
| Zinc gluconate (14.3% zinc) | 52.3 |
| | |

| | |
|-----------|--------|
| Excipient | qs 1 g |
|-----------|--------|

This type of tablet is taken twice a day.

Example 26

5

Two groups of 36 women from 18 to 40 years old approximately, having fine, lifeless and seborrheic hair, took for six months:

- either the hair formulation having the following 10 composition:

| | mg |
|---|-----|
| Taurine | 150 |
| Green tea extract (30% catechins) | 375 |
| Grapeseed extract (40% PCO and 20% catechins) | 150 |
| Zinc sulfate (22.75%) | 15* |

*expressed as weight of zinc

- or a placebo, a maltodextrin-based tablet of identical appearance.

15 The effect of the treatment was examined by self-evaluation, and by casting a comb through the hair three times at T0, T3 months and T6 months.

A uniform decrease in the number of hairs on the comb 20 was noted in the treated group, this difference being statistically significant, compared with the group at six months which received the placebo. The results are given in figure 3.

The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment 5 or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

10 Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of 15 any other integer or step or group of integers or steps.

20

25

30

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. Use of taurine and/or hypotaurine and/or salts thereof that are acceptable in an oral composition, in the preparation of an oral composition for treating and preventing aging of the pilosebaceous unit and/or alopecia.
2. A use according to claim 1, for reducing or preventing impairment of the connective tissue of the hair follicle.
3. A use according to claim 1 or 2, for reducing or preventing impairment of the hair follicle induced by rigidification of the connective sheath.
4. A use according to any one of claims 1 to 3, for reducing or preventing impairment of the hair follicle induced by excessive crosslinking and/or synthesis of natural collagens.
5. A use according to any one of claims 1 to 4, for regulating the metabolism and structure of collagens in perifollicular skin tissue.
6. A use according to any one of claims 1 to 5, for regulating the metabolism and structure of collagens in the connective sheath of the hair follicle.
7. A use according to any one of claims 1 to 6, for preventing miniaturization of the hair follicle.

- 44 -

8. A use according to any one of claims 1 to 7, wherein the daily dose of taurine and/or hypotaurine and/or acceptable salts thereof, as taurine equivalent, is between 0.5 and 4000 mg/day.

5

9. A use according to any one of claims 1 to 8 wherein the daily dose of taurine and/or hypotaurine and/or acceptable salts thereof, as taurine equivalent, is between 10 and 500 mg/day.

10

10. A use according to any one of claims 1 to 9, wherein the daily dose of taurine and/or hypotaurine and/or acceptable salts thereof, as taurine equivalent, is from 50 to 150 mg/day.

15

11. A use according to any one of claims 1 to 10, wherein that the acceptable salts of taurine and/or hypotaurine are the magnesium, manganese, iron II or zinc salts.

20

12. A use according to any one of claims 1 to 11, wherein that the taurine and/or hypotaurine and/or acceptable salts thereof are used in combination with at least one of the compounds chosen from fatty acids, polyphenols and extracts comprising the same.

25

13. A use according to any one of claims 1 to 12, wherein that the taurine and/or hypotaurine and/or acceptable salts thereof are used in combination with at least one polyphenol.

30

14. A use according to claim 13, wherein that the polyphenols are chosen from flavones, flavonols,

- 45 -

isoflavones, anthocyanins, proanthocyanidins, and stilbenes.

15. A use according to claim 13 or 14, wherein that the
5 polyphenols are chosen from catechine, epicatechin,
epigallocatechin 3-O-gallate, epigallocatechin,
epicatechin 3-gallate, procyanidins and
proanthocyanidins, and mixtures thereof.

10 16. A use according to any one of claims 13 to 15, wherein
that the daily dose of polyphenol(s) is between 0.5 and
2000 mg/day.

17. A use according to any one of claims 13 to 16, wherein
15 that the daily dose of polyphenol(s) is from about 0.5
to 1000 mg/day.

18. A use according to any one of claims 13 to 17, for
reducing or preventing hair loss.

20 19. A use according to claim 17 or 18, for reducing or
preventing the impact of testosterone on the
pilosebaceous unit.

25 20. A use according to any one of claims 1 to 19, wherein
that the taurine and/or hypotaurine and/or acceptable
salts thereof are used in combination with at least one
fatty acid.

30 21. A use according to any one of claims 12 to 20, wherein
that the fatty acid(s) are chosen from n-6 and n-3
essential polyunsaturated fatty acids, containing

- 46 -

between 18 and 22 carbon atoms, and also esters thereof, and mixtures thereof.

22. A use according to any one of claims 12 to 21, in that
5 the fatty acid(s) is (are) chosen from linoleic acid, γ -linolenic acid, linolenic acid, stearidonic acid, crocetin and 5,8,11,14-eicosatetraenoic acid, and mixtures thereof.

10 23. A use according to any one of claims 12 to 22, wherein
that the daily dose of fatty acids is between 0.5 and
3500 mg/day.

24. A use according to claim 23 wherein the daily dose of
15 fatty acids is between 5 and 1500 mg/day.

25. A use according to any one of claims 12 to 24, wherein
that the dose of n-6 fatty acids is between 0.5 and 2600
mg/day.

20 26. A use according to claim 25 wherein the dose of n-6
fatty acids is 5 to 1200 mg/day.

27. A use according to any one of claims 12 to 26, wherein
25 that the dose of n-3 fatty acids is between 0.5 and 2500
mg/day.

28. A use according to claim 27 wherein the dose of n-3
fatty acids is 5 to 360 mg/day.

30 29. A use according to any one of claims 12 to 28, wherein

the composition is in the form of a food supplement.

30. A use according to any one of claims 1 to 29, wherein
5 that the oral composition also comprises at least one of
the supplements chosen from vitamins C and E, zinc or
its salts, selenium and at least one carotenoid.

31. A use according to claim 30 wherein the at least one
10 carotenoid is chosen from β -carotene, lycopene,
zeaxanthin and lutein.

32. A composition for oral absorption, comprising, as active
15 agent, at least 0.05% to 80% by weight of taurine and/or
hypotaurine and/or salts thereof acceptable for oral
absorption, at least one polyphenol chosen from
flavanones, anthocyanins, flavonols, proanthocyanidins
and stilbenes and an excipient.

33. A composition according to claim 32, wherein that it
20 comprises at least one fatty acid and/or a salt thereof
acceptable in an oral composition.

34. A composition according to claim 32 or claim 33, wherein
25 that it comprises from 0.01% to 10% by weight of at
least one polyphenol and optionally 0.1% to 10% by
weight of at least one fatty acid.

35. A composition according to any one of claims 32 to 34,
30 wherein that it comprises 0.01% to 30% by weight of
taurine and/or hypotaurine and/or acceptable salts
thereof, in combination with 0.1% to 50% by weight of

- 48 -

extracts comprising at least one polyphenol chosen from flavonols, anthocyanins, proanthocyanidins and flavanones, and stilbenes.

5 36. A composition according to any one of claims 32 to 35, wherein that it comprises polyphenols in combination with taurine and/or hypotaurine and/or acceptable salts thereof in a polyphenol/taurine weight ratio at least equal to 0.5.

10

37. A composition according to claim 36 wherein the polyphenol/taurine weight ratio is greater than or equal to 0.75.

15

38. A composition according to claim 36 wherein the polyphenol/taurine weight ratio is greater than or equal to 1.

20

39. A composition according to any one of claims 32 to 38 wherein that it comprises at least some catechins in combination with taurine and/or hypotaurine and/or acceptable salts thereof.

25

40. A composition according to claim 39, wherein that it comprises 0.01% to 30% by weight of taurine and/or hypotaurine and/or acceptable salts thereof, in combination with 0.1% to 25% by weight of catechins.

30

41. A composition according to any one of claims 32 to 40, wherein that it also comprises at least one of the compounds chosen from vitamins C and E, zinc or its salts, selenium and at least one carotenoid.

42. A composition according to claim 41 wherein the carotenoid is chosen from β -carotene, lycopene, zeaxanthin and lutein.

5

43. A composition according to any one of claims 32 to 41, wherein that the excipient is acceptable for a food supplement, in the form of a sugarcoated tablet, a gel capsule, a gel, an emulsion, a tablet, a wafer capsule, 10 a drinkable ampule, a dilutable or nondilutable powder, dietary bars or enriched foods.

44. A composition according to any one of claims 32 to 43, wherein that it is a food supplement.

15

45. A cosmetic process for treating and preventing aging of the hair and/or alopecia via the oral administration of taurine and/or hypotaurine and/or acceptable salts thereof.

20

46. A process according to claim 45, in which the taurine, hypotaurine or acceptable salts thereof is (are) administered at a dose of from 0.5 to 4000 mg per day, as taurine equivalent.

25

47. A process according to claim 45 or 46, in which the taurine, hypotaurine and/or acceptable salts thereof is (are) used in combination with at least one of the supplements chosen from zinc, polyphenols, fatty acids, 30 vitamin C, vitamin E, and one (or more) carotenoid(s), for example β -carotene or lycopene.

- 50 -

48. A cosmetic process for treating and preventing disorders of the pilosebaceous unit via the oral administration of at least one fatty acid, one polyphenol or an extract 5 comprising the same, in combination with taurine and/or hypotaurine and/or acceptable salts thereof.

49. A process according to claim 48, in which the taurine, 10 hypotaurine or acceptable salts thereof is (are) administered at a dose of from 0.5 to 4000 mg per day, as taurine equivalent, and at least one fatty acid is administered at a dose of from 0.5 to 5400 mg/day, or a polyphenol is administered at a dose of from 0.5 to 2000 mg/day.

15 50. A use according to any one of claims 1 to 31 substantially as hereinbefore described.

51. A composition according to any one of claims 32 to 44 20 substantially as hereinbefore described.

52. A process according to any one of claims 45 to 49 substantially as hereinbefore described.

1/2




FIG. 1




FIG. 2

2/2




FIG. 3